Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

Summary

Amplitude Therapeutics and Eli Lilly announced a strategic collaboration to develop trans-amplifying RNA vaccines for infectious diseases, leveraging Amplitude's taRNA platform with Lilly's development and commercialization capabilities. Lilly retains options for up to two additional targets beyond initial programs.